The Icelandic Medicines Agency has approved an MAA filed by Medical Developments International (MVP) to allow marketing of Penthrox inhaled methoxyflurane for the treatment of pain due to traumatic injury. The company said that Penthrox would be available for sale in Iceland immediately after the approval, which was dated January 16, 2018.
In December 2017, MVP announced that Penthrox had been approved in 22 European counties, including Iceland, through the Decentralized Procedure. The inhaler is already approved and available in the UK, Ireland, France, and Belgium.
MVP CEO John Sharman commented, “It is great to see the first Marketing Authorization come through so quickly. We expect the other 21 countries will issue Marketing Authorizations to approve the sale of Penthrox in their country over the coming months.”
He added, “It is a very proud moment to see Australia’s first choice, front line analgesic being used by doctors, hospitals and ambulances throughout Europe. There are no other drugs like Penthrox. The opportunities for Penthrox to treat patients with moderate to severe pain without the need to use dangerous opioids should drive our rapid expansion globally.”
Read the MVP press release.
